Cancer vaccines: progress reveals new complexities.

Cancer vaccines: progress reveals new complexities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cancer vaccines: progress reveals new complexities. Abstract Text:

Zhiya Yu,Nicholas P Restifo,

Cancer vaccines: progress reveals new complexities. Publishing Authors By Initials

Z Yu,NP Restifo,

For similar neoplasms research abstracts see: neoplasms research

PUBMED ID PMID:

MEDLINE DATE:

Cancer vaccines: progress reveals new complexities. Journal Published:

PUBLICATION TYPE: Review

Journal: The Journal of clinical investigation

VOLUME: 110

Page Numbers: 289-94

Journal Abbreviation: J. Clin. Invest.

ISSN: 0021-9738

DAY: 28

MONTH: Aug

YEAR: 2002

Cancer vaccines: progress reveals new complexities. Information

Number of References: 56

LANGUAGE: eng

NlmUniqueID: 7802877

Cancer vaccines: progress reveals new complexities. Keywords Mesh Terms:

KEYWORDS: Neoplasms

MESH TERMS: prevention & control

Chemical & Substance for Abstract: Cancer vaccines: progress reveals new complexities. Information

Substance Name: Epitopes, T-Lymphocyte

Registry Number: 0

Grant and Affiliation Information for Cancer vaccines: progress reveals new complexities.

AFFILIATION: National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-1502, USA.

Country: United States

AGENCY: United States NCI

GRANT: Z01 BC010763-01

ACRONYM: BC

MEDLINETA: J Clin Invest

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cancer vaccines: progress reveals new complexities Related Publications

• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.
• Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.
• Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other".
• Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity.
• CD8+ T-cell memory in tumor immunology and immunotherapy.
• Cancer vaccines: progress reveals new complexities.
• Countering the 'counterattack' hypothesis.
• Creating therapeutic cancer vaccines: notes from the battlefield.
• Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen.
• Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases.
• DNA and RNA-based vaccines: principles, progress and prospects.
• Do CD4+ CD25+ immunoregulatory T cells hinder tumor immunotherapy?
• Enhancement of tumor-specific immune response with plasmid DNA replicon vectors.
• Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function.
• Hierarchy, tolerance, and dominance in the antitumor T-cell response.
• IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: enhancement by simultaneous B7-1 expression.
• IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.
• Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice.
• Insertion signal sequence fused to minimal peptides elicits specific CD8+ T-cell responses and prolongs survival of thymoma-bearing mice.
• Minimal determinant expressed by a recombinant vaccinia virus elicits therapeutic antitumor cytolytic T lymphocyte responses.
• Mining the melanosome for tumor vaccine targets: P.polypeptide is a novel tumor-associated antigen.
• Natural selection of tumor variants in the generation of "tumor escape" phenotypes.
• NeuronMetrics: software for semi-automated processing of cultured neuron images.
• Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1.
• Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape.
• Synthetic oligonucleotide expressed by a recombinant vaccinia virus elicits therapeutic CTL.
• The future of interleukin-2: enhancing therapeutic anticancer vaccines.
• Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
• Toll-like receptors in tumor immunotherapy.
• Vaccines to die for.